Mississippi Clinical Trials Report — June 2026

For Mississippians considering participation in clinical research, June 2026 presents both urgent opportunities and fresh avenues for contribution. With 16 clinical trials statewide slated to conclude within the next 90 days, time is of the essence for those interested in specific areas of research. This includes one crucial study that is actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition before its enrollment window closes.

Individuals living with certain health conditions should act quickly to explore trials with impending deadlines. Research focusing on various conditions, from cardiovascular health to neurological disorders, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Age-related macular degeneration
• Atrial fibrillation (AF)
• Attention-deficit/hyperactivity disorder
• Avascular necrosis
• Bronchopulmonary dysplasia
• Chronic granulomatous disease (CGD)
• Chronic kidney disease
• Chronic lung disease of prematurity
• COVID-19
• Dementia, vascular

If you or a loved one are affected by one of these conditions, we encourage you to review the available trials promptly to see if you might be eligible to participate.

New Research Initiatives Launch Across Mississippi

This month, Mississippi welcomes 6 new clinical trials, a slight increase from the 5 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and acute migraine.

Leading the new research opportunities are two prominent sponsors, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, and Kallyope Inc., both bringing important Phase 3 studies to the state:

• Gasherbrum Bio, Inc. is sponsoring NCT07654361, a Phase 3 "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This substantial global study aims to enroll 3,600 participants, evaluating the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for weight management.
• Another major Phase 3 trial from Gasherbrum Bio, Inc. is NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This randomized, double-blind, placebo-controlled study will investigate the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and type 2 diabetes mellitus (T2DM) over 76 weeks of treatment, with a target of 1,100 participants.
• For individuals experiencing migraines, Kallyope Inc. is leading NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter, outpatient evaluation will assess the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine, aiming for 1,800 participants.
• Kallyope Inc. is also sponsoring NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3 study focuses on evaluating the safety and tolerability of intermittent use of elismetrep over the long term for acute migraine attacks, with a goal of 1,000 participants.

Expanding Research Opportunities Across Conditions

The 6 new trials opening this month in Mississippi cover a diverse range of health conditions, with a strong focus on metabolic health and neurological conditions. The most common conditions addressed by these new studies include:

• Chronic weight management (2 trials)
• Obesity (2 trials)
• Overweight (2 trials)
• Acute migraine (1 trial)
• Migraine (1 trial)
• Type 2 diabetes mellitus (1 trial)
• Temporomandibular disorder (1 trial)
• Spinal cord injuries (1 trial)

In terms of intervention types, drug trials lead the way, accounting for 4 of the new studies. Additionally, 1 new device trial and 1 other type of research have also commenced, reflecting a broad approach to medical innovation.

Geographic Reach: New Trials in Key Cities

Mississippi's clinical research landscape continues to be robust, with 364 clinical trials currently recruiting across 39 cities and 230 research sites statewide. This month, new research initiatives are opening in several key locations, expanding access for residents. New trials have opened in cities including Ridgeland, Gulfport, and Hattiesburg, ensuring that opportunities for participation are available beyond the largest metropolitan areas.

Healthy Volunteers and Diverse Demographics Welcome

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 6 new trials launched this month, 1 is actively seeking healthy volunteers. Statewide, a total of 24 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Mississippi are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 1 includes children as participants, and 6 include older adults, ensuring that research benefits diverse age groups. Industry sponsors are driving significant research efforts this month, with 5 new trials sponsored by pharmaceutical companies such as Gasherbrum Bio, Inc. and Kallyope Inc., while 1 new trial is sponsored by an academic institution, William Carey University.

As June progresses, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments and preventive measures for a broad spectrum of health challenges across Mississippi. We encourage all interested individuals to explore these opportunities and consider contributing to the future of medicine.